Supplement evidence

047 / 575Experimental longevity

NMN

View my plan →

The short answer

Short human trials show that oral NMN can alter NAD-related biomarkers.

Evidence and scope: Emerging evidence
This status does not grade the ingredient for every goal, outcome, or person.
Important limitation: Biomarker changes have not demonstrated reduced disease, disability, or longer human life.
Before deciding: Long-term safety, effective dosing, and product quality remain uncertain.

01 / PRACTICAL GUIDE

Dose, absorption, and combinations

These are indication-specific reference or studied ranges—not a personalized prescription. Start with the objective, then check the form, label, medicines, and health conditions.

Reference range by objective

Meeting usual needs250–1,200 mg/day in short early-phase human trials; no established health dose

Reference or studied range—not a personalized prescription. The product label or a clinician may specify a different dose.

Dose source ↗

More is not automatically better. A clinician or product label may specify a different amount.

Absorption / solubilityWater-soluble

Water-soluble or readily water-dispersible. This does not mean excess is always harmless.

How it is commonly taken

Timing is not established.

Do not combine casually

Do not combine experimental longevity compounds during pregnancy, cancer treatment, or without reviewing medicines and product purity.

Dose and use source ↗

Dose and use links lead to primary or official source material. Search links are discovery tools, not proof that every returned paper applies.

02 / EVIDENCE

What the research says

We keep supportive, mixed, negative, safety, and contextual findings together. The headline never replaces the underlying papers.

5research papers in this ledger

5unique primary studies represented

243unique participants represented

These are audited counts for this JIVANA collection, not search-result totals. Participants are counted once when multiple papers use the same cohort; review papers are not added again to participant totals.

Open the research timelineResearch timeline

Entries are ordered by publication year. A study period appears only when the source reports it.

2023

Mixed or qualifiedPMID 36482258 · NCT04823260

The efficacy and safety of β-nicotinamide mononucleotide supplementation in healthy middle-aged adults

NAD concentrations rose and selected secondary measures changed; no lifespan or major clinical outcome was tested.

Published: 2023Duration: 60 daysn=80 participants

Study design and methods

Design: Randomized, multicenter, double-blind, dose-ranging trial
Population: Healthy middle-aged adults
Intervention: Placebo or NMN 300, 600, or 900 mg/day
Outcome: Blood NAD, walking test, biomarkers, and short-term safety

Funding or conflict note: Several author affiliations were with companies involved in NMN products or research.

Open research record ↗

2022

Supports a specific usePMID 35479740 · jRCTs041200034

Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood NAD Levels in Healthy Subjects

NMN increased blood NAD levels and was tolerated over 12 weeks; this is a biomarker result, not a longevity outcome.

Published: 2022Duration: 12 weeksn=30 participants

Study design and methods

Design: Randomized, double-blind, placebo-controlled trial
Population: Healthy adults
Intervention: NMN 250 mg/day versus placebo
Outcome: Blood NAD metabolites and short-term safety

Funding or conflict note: The supplement and placebo were prepared by an employer of several authors.

Open research record ↗

2022

Mixed or qualifiedPMID 35927255

Chronic nicotinamide mononucleotide supplementation elevates blood NAD levels and alters muscle function in healthy older men

NMN increased NAD-related metabolites and changed selected muscle-function measures; the trial was small and did not test clinical longevity.

Published: 2022Duration: 6 or 12 weeksn=42 participants

Study design and methods

Design: Randomized, double-blind, placebo-controlled trial
Population: Healthy older men
Intervention: NMN 250 mg/day versus placebo
Outcome: Blood NAD metabolites and muscle function

Open research record ↗

2022

Mixed or qualifiedPMID 35821806

A Multicentre, Randomised, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Uthever

The product increased a serum NAD/NADH measure; short duration and manufacturer involvement limit interpretation.

Published: 2022Duration: 60 daysn=66 participants

Study design and methods

Design: Randomized, double-blind, placebo-controlled trial
Population: Healthy adults aged 40–65
Intervention: NMN 300 mg/day versus placebo
Outcome: Serum NAD/NADH and quality-of-life measures

Funding or conflict note: The sole listed affiliation was the product manufacturer.

Open research record ↗

2021

Supports a specific usePMID 33888596 · NCT03151239

Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women

NMN improved muscle insulin sensitivity and signaling in this small, specific population; it did not test lifespan.

Published: 2021Duration: 10 weeksn=25 participants

Study design and methods

Design: Randomized, double-blind, placebo-controlled trial
Population: Postmenopausal women with prediabetes and overweight or obesity
Intervention: NMN versus placebo
Outcome: Muscle insulin sensitivity and signaling

Open research record ↗

Unscreened discovery appendix—not evidence49 candidate publicationsSearch run: Aug 21, 2026

Complete for the displayed PubMed query at the search timestamp—not for all databases or every possible synonym. Candidates can be irrelevant, duplicate the same study, or report negative findings. They are never summed as evidence or participants until screened.

03 / SOURCES

Start with the source material

Official evidence overviewPubMed human-evidence index Live PubMed discovery searchNational Library of Medicine

The live search is for discovery only. Search-result counts change and are not included in the audited totals above.

Recent PubMed discovery recordsDirect links to the first 12 records returned by the reproducible search. These are discovery candidates—not reviewed summaries or a count of supportive findings.

04 / EXPERT CONTEXT

Expert context—not evidence

Expert positions are dated context—not scientific evidence. They never raise the evidence status or become consensus by repetition.

No direct, source-verified endorsement is currently recorded. Research authorship or discussion alone is not treated as endorsement.